NAT1 (N-acetyltransferase 1 (arylamine N-acetyltransferase))

Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home Genes Leukemias Solid Tumors Cancer-Prone Deep Insight Case Reports Journals Portal Teaching

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

NAT1 (N-acetyltransferase 1 (arylamine N-acetyltransferase))

Written	2009-02	Jhon D Ruiz, José AG Agúndez, Carmen Martínez, Elena García-Martín
		Department of Pharmacology, Medical School, University of Extremadura, Badajoz, Spain (JDR, JAGA, CM); Department of Biochemistry & Molecular biology & Genetics, School of Biological Sciences, Badajoz, Spain (EGM)

(Note : for Links provided by Atlas : click)

Identity

Alias_names	AAC1
	N-acetyltransferase 1 (arylamine N-acetyltransferase)
Other alias	MNAT
HGNC (Hugo)	NAT1
LocusID (NCBI)	9
Atlas_Id	41497
Location	8p22 [Link to chromosome band 8p22]
Location_base_pair	Starts at 18210103 and ends at 18223689 bp from pter ( according to hg19-Feb_2009) [Mapping NAT1.png]


	Picture adapted from an original prepared by Genetics Home Reference; February 2009.

Fusion genes
(updated 2016)

NAT1 (8p22) / NAT1 (8p22)

DNA/RNA

Note	In humans NAT1 is located in the NAT cluster that comprises 230 kb and includes two functional genes, NAT1 and NAT2. In other species the number of NAT genes range from 0 to 4.


	Structure of the human NAT1 gene and common NAT1 transcripts.

Transcription	The human NAT1 gene has nine exons. The coding region is located in exon 9 and spans 870 bp. Diverse NAT1 transcripts have been reported and two promoters exist. The first promoter, designated as P1 is located in the 5' flanking region of exon 1 and controls two major (a1 and a2) transcripts. The second promoter is located upstream of exon 4 and give rise to at least five (b1 to b5) different transcripts. The different transcripts appear to have different translational efficiencies, although the biological significance of this is unknown (revised in Butcher et al., 2007).
Pseudogene	In humans the NAT locus has a pseudogene designated as NATP.

Protein

Note	NAT enzymes have been identified in several vertebrate and microorganism species, whereas NAT deficiency in the domestic and wild dog is due to complete absence of NAT genes.

Description	The amino-terminal domain (residues 1-83) consists of five helices and one short beta-strand. The second domain comprises residues 85-192 and consists of nine beta-strands and two short helices. The third domain has a final helix which precedes the carboxy terminal region.
Expression	NAT1 activity is expressed in liver and in many extrahepatic tissues. The transcripts originated from the first promoter, NATa, are expressed in kidney, liver, lung and trachea. However the most common transcripts are those designated as type b in the Figure above and have been detected in all tissues examinated.
Localisation	Arylamine N-acetyltransferases are cytosolic enzymes.
Function	NAT1 is a phase II enzyme that participates in the metabolism of numerous primary arylamines and hydrazine drugs and carcinogens. In addition to their N-acetylation catalytic activity, NAT enzymes have also O-acetylation activity towards N-hydroxyarylamines.
Homology	NAT1 and NAT2 share 87% nucleotide homology in the coding region, whereas NAT1 and NAT2 proteins share 81% amino-acid sequence identity.

Mutations

Note	In humans NAT1 is highly polymorphic. Several polymorphisms, most of which are single nucleotide polymorphisms, and at least 26 different haplotypes have been described. The Figure below shows the positions of NAT1 polymorphisms, taking as a reference the start site in the open reading frame (ORF) in exon 9. Nonsynonymous polymorphisms are labeled in red font. The association of different haplotypes with phenotypes is summarized in the following link: http://louisville.edu/medschool/pharmacology/Human.NAT1.pdf.

Implicated in

Note

Entity	Lung cancer
Note	Two independent studies have observed a significant association of the NAT1 polymorphism with lung cancer risk (Bouchardy et al., 1998; Wikman et al., 2001). However these studies should be interpreted cautiously because these do not agree on the NAT1 risk genotype. Another study identified an increased risk among carriers of NAT1 plus NAT2 slow genotypes (Gemignani et al., 2007). In a meta-analysis carried out with smokers that suffered from non small-cell lung cancer a relevant association of the NAT1 rapid acetylation genotype was identified (Zienolddiny et al., 2008). Although negative associations have been reported (Perera et al., 2006 ), NAT1 is emerging as the NAT gene most likely related to lung cancer (McKay et al, 2008).


Entity	Head and neck cancer
Note	Since chemical compounds present in tobacco are inactivated by phase II enzymes, it has been proposed that head and neck cancer risk could be modified by NAT genotypes. Head and neck cancers are strongly associated with smoking, and a few studies have explored the role of NAT1 polymorphisms in the risk of developing head and neck cancer in smokers. However overall findings are inconsistent and associations if present are weak, and indicate either a decreased risk in carriers of the variant NAT1*10 (McKay et al., 2008), an increased risk (Katoh et al., 1998) or a lack of association (Fronhoffs et al., 2001; Henning et al., 1999; Agúndez, 2008).


Entity	Breast cancer
Note	The NAT1*10 variant allele was associated to increased breast cancer risk among women who consumed well-done meat, although the statistical significance of this finding is low (Krajinovic et al., 2001). Several studies, however, indicate that no major association of NAT polymorphisms and breast cancer risk exists (Agúndez, 2008).


Entity	Colorectal cancer
Note	A biologically plausible mechanistic hypothesis suggest that rapid NAT1 and/or NAT2 acetylators should more activate heterocyclic amine carcinogens within the colon to their ultimate carcinogenic forms, thereby predisposing them to colorectal cancer. However sufficient evidence is available to rule out a relevant association of NAT genotypes alone with colorectal cancer risk. This evidence is based in nearly thirty studies failed to detect a statistically significant association for NAT1 genotypes both with colorectal cancer or adenomas. In addition meta-analyses (Chen et al., 2005; Ye et al., 2002; Houlston et al., 2001) consistently confirm a lack of a relevant association of NAT1 rapid acetylator genotypes and colorectal cancer risk (revised in Agúndez, 2008).


Entity	Bladder cancer
Note	No significant association of the NAT1 genotype with bladder cancer risk has been observed in a recent meta-analysis, although the authors found a joint effect of NAT1 rapid genotypes, slow NAT2 genotypes and smoking as factors increasing cancer risk (Sanderson et al., 2007). Overall findings are negative (Okkels et al., 1997), although a significant risk has been described in smokers (Taylor et al., 1998; Hsieh et al., 1999; Cascorbi et al., 2001) and a nearly significant association was observed in individuals exposed to benzidine (Carreon et al., 2006).

Bibliography

Polymorphisms of human N-acetyltransferases and cancer risk.

Agundez JA.

Curr Drug Metab. 2008 Jul;9(6):520-31.

PMID 18680472

Functional properties of an alternative, tissue-specific promoter for human arylamine N-acetyltransferase 1.

Barker DF, Husain A, Neale JR, Martini BD, Zhang X, Doll MA, States JC, Hein DW.

Pharmacogenet Genomics. 2006 Jul;16(7):515-25.

PMID 16788383

Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression.

Blum M, Grant DM, McBride W, Heim M, Meyer UA.

DNA Cell Biol. 1990 Apr;9(3):193-203.

PMID 2340091

N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk.

Bouchardy C, Mitrunen K, Wikman H, Husgafvel-Pursiainen K, Dayer P, Benhamou S, Hirvonen A.

Pharmacogenetics. 1998 Aug;8(4):291-8.

PMID 9731715

Induction of human arylamine N-acetyltransferase type I by androgens in human prostate cancer cells.

Butcher NJ, Tetlow NL, Cheung C, Broadhurst GM, Minchin RF.

Cancer Res. 2007 Jan 1;67(1):85-92.

PMID 17210686

NAT2 slow acetylation and bladder cancer in workers exposed to benzidine.

Carreon T, Ruder AM, Schulte PA, Hayes RB, Rothman N, Waters M, Grant DJ, Boissy R, Bell DA, Kadlubar FF, Hemstreet GP 3rd, Yin S, LeMasters GK.

Int J Cancer. 2006 Jan 1;118(1):161-8.

PMID 16003747

Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10.

Cascorbi I, Roots I, Brockmoller J.

Cancer Res. 2001 Jul 1;61(13):5051-6.

PMID 11431340

Relationship between metabolic enzyme polymorphism and colorectal cancer.

Chen K, Jiang QT, He HQ.

World J Gastroenterol. 2005 Jan 21;11(3):331-5.

PMID 15637738

Classification of breast cancer using genetic algorithms and tissue microarrays.

Dolled-Filhart M, Ryden L, Cregger M, Jirstrom K, Harigopal M, Camp RL, Rimm DL.

Clin Cancer Res. 2006 Nov 1;12(21):6459-68.

PMID 17085660

Real-time PCR analysis of the N-acetyltransferase NAT1 allele *3, *4, *10, *11, *14 and *17 polymorphism in squamous cell cancer of head and neck.

Fronhoffs S, Bruning T, Ortiz-Pallardo E, Brode P, Koch B, Harth V, Sachinidis A, Bolt HM, Herberhold C, Vetter H, Ko Y.

Carcinogenesis. 2001 Sep;22(9):1405-12.

PMID 11532862

Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes.

Gemignani F, Landi S, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rudnai P, Fabianova E, Mates D, Foretova L, Janout V, Bencko V, Gaborieau V, Gioia-Patricola L, Bellini I, Barale R, Canzian F, Hall J, Boffetta P, Hung RJ, Brennan P.

Carcinogenesis. 2007 Jun;28(6):1287-93. Epub 2007 Jan 27.

PMID 17259654

Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes.

Grant DM, Blum M, Beer M, Meyer UA.

Mol Pharmacol. 1991 Feb;39(2):184-91.

PMID 1996083

Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians.

Gu J, Liang D, Wang Y, Lu C, Wu X.

Mutat Res. 2005 Mar 7;581(1-2):97-104. Epub 2004 Dec 16.

PMID 15725609

Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms.

Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, Devanaboyina US, Nangju NA, Feng Y.

Cancer Epidemiol Biomarkers Prev. 2000 Jan;9(1):29-42.

PMID 10667461

Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis.

Hein DW.

Mutat Res. 2002 Sep 30;506-507:65-77.

PMID 12351146

Association of arylamine N-acetyltransferases NAT1 and NAT2 genotypes to laryngeal cancer risk.

Henning S, Cascorbi I, Munchow B, Jahnke V, Roots I.

Pharmacogenetics. 1999 Feb;9(1):103-11.

PMID 10208649

Polymorphisms and colorectal tumor risk.

Houlston RS, Tomlinson IP.

Gastroenterology. 2001 Aug;121(2):282-301.

PMID 11487538.

Genetic polymorphisms of N-acetyltransferase 1 and 2 and risk of cigarette smoking-related bladder cancer.

Hsieh FI, Pu YS, Chern HD, Hsu LI, Chiou HY, Chen CJ.

Br J Cancer. 1999 Oct;81(3):537-41.

PMID 10507782

Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe.

Hughes NC, Janezic SA, McQueen KL, Jewett MA, Castranio T, Bell DA, Grant DM.

Pharmacogenetics. 1998 Feb;8(1):55-66.

PMID 9511182

Identification of the major promoter and non-coding exons of the human arylamine N-acetyltransferase 1 gene (NAT1).

Husain A, Barker DF, States JC, Doll MA, Hein DW.

Pharmacogenetics. 2004 Jul;14(7):397-406.

PMID 15226672

Functional analysis of the human N-acetyltransferase 1 major promoter: quantitation of tissue expression and identification of critical sequence elements.

Husain A, Zhang X, Doll MA, States JC, Barker DF, Hein DW.

Drug Metab Dispos. 2007 Sep;35(9):1649-56. Epub 2007 Jun 25.

PMID 17591675

1998 International Meeting on the Arylamine N-Acetyltransferases: synopsis of the workshop on nomenclature, biochemistry, molecular biology, interspecies comparisons, and role in human disease risk.

Ilett KF, Kadlubar FF, Minchin RF.

Drug Metab Dispos. 1999 Sep;27(9):957-9.

PMID 10460790

Loss of function polymorphisms in NAT1 protect against spina bifida.

Jensen LE, Hoess K, Mitchell LE, Whitehead AS.

Hum Genet. 2006 Aug;120(1):52-7. Epub 2006 May 6.

PMID 16680433

Role of arylamine N-acetyltransferase 1 and 2 (NAT1 and NAT2) genotypes in susceptibility to oral/pharyngeal and laryngeal cancers.

Jourenkova-Mironova N, Wikman H, Bouchardy C, Mitrunen K, Dayer P, Benhamou S, Hirvonen A.

Pharmacogenetics. 1999 Aug;9(4):533-7.

PMID 10780274

Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping.

Kashuba AD, Bertino JS Jr, Kearns GL, Leeder JS, James AW, Gotschall R, Nafziger AN.

Clin Pharmacol Ther. 1998 May;63(5):540-51.

PMID 9630827

A pilot study testing the association between N-acetyltransferases 1 and 2 and risk of oral squamous cell carcinoma in Japanese people.

Katoh T, Kaneko S, Boissy R, Watson M, Ikemura K, Bell DA.

Carcinogenesis. 1998 Oct;19(10):1803-7.

PMID 9806162

Genetic susceptibility to breast cancer in French-Canadians: role of carcinogen-metabolizing enzymes and gene-environment interactions.

Krajinovic M, Ghadirian P, Richer C, Sinnett H, Gandini S, Perret C, Lacroix A, Labuda D, Sinnett D.

Int J Cancer. 2001 Apr 15;92(2):220-5.

PMID 11291049

Variants of N-acetyltransferase NAT1 and a case-control study of colorectal adenomas.

Lin HJ, Probst-Hensch NM, Hughes NC, Sakamoto GT, Louie AD, Kau IH, Lin BK, Lee DB, Lin J, Frankl HD, Lee ER, Hardy S, Grant DM, Haile RW.

Pharmacogenetics. 1998 Jun;8(3):269-81.

PMID 9682272

Arylamine N-acetyltransferase aggregation and constitutive ubiquitylation.

Liu F, Zhang N, Zhou X, Hanna PE, Wagner CR, Koepp DM, Walters KJ.

J Mol Biol. 2006 Aug 18;361(3):482-92. Epub 2006 Jun 30.

PMID 16857211

Sequence variants of NAT1 and NAT2 and other xenometabolic genes and risk of lung and aerodigestive tract cancers in Central Europe.

McKay JD, Hashibe M, Hung RJ, Wakefield J, Gaborieau V, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, Rudnai P, Fabianova E, Mates D, Foretova L, Janout V, Bencko V, Chabrier A, Hall J, Boffetta P, Canzian F, Brennan P.

Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):141-7.

PMID 18199719

Arylamine N-acetyltransferase I.

Minchin RF, Hanna PE, Dupret JM, Wagner CR, Rodrigues-Lima F, Butcher NJ.

Int J Biochem Cell Biol. 2007;39(11):1999-2005. Epub 2007 Jan 20.

PMID 17392017

Acetylation of p-aminobenzoylglutamate, a folic acid catabolite, by recombinant human arylamine N-acetyltransferase and U937 cells.

Minchin RF.

Biochem J. 1995 Apr 1;307 ( Pt 1):1-3.

PMID 7717963

Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.

Okkels H, Sigsgaard T, Wolf H, Autrup H.

Cancer Epidemiol Biomarkers Prev. 1997 Apr;6(4):225-31.

PMID 9107426

Lack of associations among cancer and albumin adducts, ras p21 oncoprotein levels, and CYP1A1, CYP2D6, NAT1, and NAT2 in a nested case-control study of lung cancer within the physicians' health study.

Perera FP, Tang D, Brandt-Rauf P, Santella RM, Mooney LV, Tu YH, Bendkowska I, Bell DA.

Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1417-9.

PMID 16835348

Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer.

Ring BZ, Seitz RS, Beck R, Shasteen WJ, Tarr SM, Cheang MC, Yoder BJ, Budd GT, Nielsen TO, Hicks DG, Estopinal NC, Ross DT.

J Clin Oncol. 2006 Jul 1;24(19):3039-47.

PMID 16809728

Homology modelling and structural analysis of human arylamine N-acetyltransferase NAT1: evidence for the conservation of a cysteine protease catalytic domain and an active-site loop.

Rodrigues-Lima F, Delomenie C, Goodfellow GH, Grant DM, Dupret JM.

Biochem J. 2001 Jun 1;356(Pt 2):327-34.

PMID 11368758

Joint effects of the N-acetyltransferase 1 and 2 (NAT1 and NAT2) genes and smoking on bladder carcinogenesis: a literature-based systematic HuGE review and evidence synthesis.

Sanderson S, Salanti G, Higgins J.

Am J Epidemiol. 2007 Oct 1;166(7):741-51. Epub 2007 Aug 4.

PMID 17675654

The role of N-acetylation polymorphisms in smoking-associated bladder cancer: evidence of a gene-gene-exposure three-way interaction.

Taylor JA, Umbach DM, Stephens E, Castranio T, Paulson D, Robertson C, Mohler JL, Bell DA.

Cancer Res. 1998 Aug 15;58(16):3603-10.

PMID 9721868

Cytosolic arylamine N-acetyltransferase (NAT) deficiency in the dog and other canids due to an absence of NAT genes.

Trepanier LA, Ray K, Winand NJ, Spielberg SP, Cribb AE.

Biochem Pharmacol. 1997 Jul 1;54(1):73-80.

PMID 9296352

Arylamine N-acetyltransferases - of mice, men and microorganisms.

Upton A, Johnson N, Sandy J, Sim E.

Trends Pharmacol Sci. 2001 Mar;22(3):140-6.

PMID 11239577

Purification of recombinant human N-acetyltransferase type 1 (NAT1) expressed in E. coli and characterization of its potential role in folate metabolism.

Ward A, Summers MJ, Sim E.

Biochem Pharmacol. 1995 Jun 16;49(12):1759-67.

PMID 7598738

Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility.

Wikman H, Thiel S, Jager B, Schmezer P, Spiegelhalder B, Edler L, Dienemann H, Kayser K, Schulz V, Drings P, Bartsch H, Risch A.

Pharmacogenetics. 2001 Mar;11(2):157-68.

PMID 11266080

Structural basis of substrate-binding specificity of human arylamine N-acetyltransferases.

Wu H, Dombrovsky L, Tempel W, Martin F, Loppnau P, Goodfellow GH, Grant DM, Plotnikov AN.

J Biol Chem. 2007 Oct 12;282(41):30189-97. Epub 2007 Jul 26.

PMID 17656365

Meta-analysis of 20 case-control studies on the N-acetyltransferase 2 acetylation status and colorectal cancer risk.

Ye Z, Parry JM.

Med Sci Monit. 2002 Aug;8(8):CR558-65.

PMID 12165742

A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers.

Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland LB, Canzian F, Haugen A.

Carcinogenesis. 2008 Jun;29(6):1164-9. Epub 2008 Feb 6.

PMID 18258609

Citation

This paper should be referenced as such :

Ruiz, JD ; Agúndez, JAG ; Martinez, C ; Garcia-Martin, E

NAT1 (N-acetyltransferase 1 (arylamine N-acetyltransferase))

Atlas Genet Cytogenet Oncol Haematol. 2010;14(1):39-43.

Free journal version : [ pdf ] [ DOI ]

On line version : http://AtlasGeneticsOncology.org/Genes/NAT1ID41497ch8p22.html

External links

	Nomenclature
HGNC (Hugo)	NAT1 7645
	Cards
Atlas	NAT1ID41497ch8p22
Entrez_Gene (NCBI)	NAT1 9 N-acetyltransferase 1
Aliases	AAC1; MNAT; NAT-1; NATI
GeneCards (Weizmann)	NAT1
Ensembl hg19 (Hinxton)	ENSG00000171428 [Gene_View]
Ensembl hg38 (Hinxton)	ENSG00000171428 [Gene_View] chr8:18210103-18223689 [Contig_View] NAT1 [Vega]
ICGC DataPortal	ENSG00000171428
TCGA cBioPortal	NAT1
AceView (NCBI)	NAT1
Genatlas (Paris)	NAT1
WikiGenes	9
SOURCE (Princeton)	NAT1
Genetics Home Reference (NIH)	NAT1
	Genomic and cartography
GoldenPath hg38 (UCSC)	NAT1 - chr8:18210103-18223689 + 8p22 [Description] (hg38-Dec_2013)
GoldenPath hg19 (UCSC)	NAT1 - 8p22 [Description] (hg19-Feb_2009)
Ensembl	NAT1 - 8p22 [CytoView hg19] NAT1 - 8p22 [CytoView hg38]
Mapping of homologs : NCBI	NAT1 [Mapview hg19] NAT1 [Mapview hg38]
OMIM	108345
	Gene and transcription
Genbank (Entrez)	###############################################################################################################################################################################################################################################################
RefSeq transcript (Entrez)	NM_000662 NM_001160170 NM_001160171 NM_001160172 NM_001160173 NM_001160174 NM_001160175 NM_001160176 NM_001160179 NM_001291962
RefSeq genomic (Entrez)
Consensus coding sequences : CCDS (NCBI)	NAT1
Cluster EST : Unigene	Hs.591847 [ NCBI ]
CGAP (NCI)	Hs.591847
Alternative Splicing Gallery	ENSG00000171428
Gene Expression	NAT1 [ NCBI-GEO ] NAT1 [ EBI - ARRAY_EXPRESS ] NAT1 [ SEEK ] NAT1 [ MEM ]
Gene Expression Viewer (FireBrowse)	NAT1 [ Firebrowse - Broad ]
SOURCE (Princeton)	Expression in : [Datasets] [Normal Tissue Atlas] [carcinoma Classsification] [NCI60]
Genevisible	Expression in : [tissues] [cell-lines] [cancer] [perturbations]
BioGPS (Tissue expression)	9
GTEX Portal (Tissue expression)	NAT1
	Protein : pattern, domain, 3D structure
UniProt/SwissProt	P18440 [function] [subcellular_location] [family_and_domains] [pathology_and_biotech] [ptm_processing] [expression] [interaction]
NextProt	P18440 [Sequence] [Exons] [Medical] [Publications]
With graphics : InterPro	P18440
Splice isoforms : SwissVar	P18440
Catalytic activity : Enzyme	2.3.1.5 [ Enzyme-Expasy ] 2.3.1.5 2.3.1.5 [ IntEnz-EBI ] 2.3.1.5 [ BRENDA ] 2.3.1.5 [ KEGG ]
PhosPhoSitePlus	P18440
Domains : Interpro (EBI)	Arylamine_N-AcTrfase
Domain families : Pfam (Sanger)	Acetyltransf_2 (PF00797)
Domain families : Pfam (NCBI)	pfam00797
Conserved Domain (NCBI)	NAT1
DMDM Disease mutations	9
Blocks (Seattle)	NAT1
PDB (SRS)	2DSS 2GWU 2IJA 2PQT
PDB (PDBSum)	2DSS 2GWU 2IJA 2PQT
PDB (IMB)	2DSS 2GWU 2IJA 2PQT
PDB (RSDB)	2DSS 2GWU 2IJA 2PQT
Structural Biology KnowledgeBase	2DSS 2GWU 2IJA 2PQT
SCOP (Structural Classification of Proteins)	2DSS 2GWU 2IJA 2PQT
CATH (Classification of proteins structures)	2DSS 2GWU 2IJA 2PQT
Superfamily	P18440
Human Protein Atlas	ENSG00000171428
Peptide Atlas	P18440
HPRD	00149
IPI	IPI00644361 IPI00930394
	Protein Interaction databases
DIP (DOE-UCLA)	P18440
IntAct (EBI)	P18440
FunCoup	ENSG00000171428
BioGRID	NAT1
STRING (EMBL)	NAT1
ZODIAC	NAT1
	Ontologies - Pathways
QuickGO	P18440
Ontology : AmiGO	arylamine N-acetyltransferase activity cytosol xenobiotic metabolic process
Ontology : EGO-EBI	arylamine N-acetyltransferase activity cytosol xenobiotic metabolic process
Pathways : KEGG	Caffeine metabolism Drug metabolism - other enzymes Chemical carcinogenesis
REACTOME	P18440 [protein]
REACTOME Pathways	R-HSA-156582 [pathway]
NDEx Network	NAT1
Atlas of Cancer Signalling Network	NAT1
Wikipedia pathways	NAT1
	Orthology - Evolution
OrthoDB	9
GeneTree (enSembl)	ENSG00000171428
Phylogenetic Trees/Animal Genes : TreeFam	NAT1
HOVERGEN	P18440
HOGENOM	P18440
Homologs : HomoloGene	NAT1
Homology/Alignments : Family Browser (UCSC)	NAT1
	Gene fusions - Rearrangements
	Polymorphisms : SNP and Copy number variants
NCBI Variation Viewer	NAT1 [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)	NAT1
dbVar	NAT1
ClinVar	NAT1
1000_Genomes	NAT1
Exome Variant Server	NAT1
ExAC (Exome Aggregation Consortium)	NAT1 (select the gene name)
Genetic variants : HAPMAP	9
Genomic Variants (DGV)	NAT1 [DGVbeta]
DECIPHER	NAT1 [patients] [syndromes] [variants] [genes]
CONAN: Copy Number Analysis	NAT1
	Mutations
ICGC Data Portal	NAT1
TCGA Data Portal	NAT1
Broad Tumor Portal	NAT1
OASIS Portal	NAT1 [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMIC	NAT1 [overview] [genome browser] [tissue] [distribution]
Mutations and Diseases : HGMD	NAT1
LOVD (Leiden Open Variation Database)	Whole genome datasets
LOVD (Leiden Open Variation Database)	LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)	LOVD 3.0 shared installation
BioMuta	search NAT1
DgiDB (Drug Gene Interaction Database)	NAT1
DoCM (Curated mutations)	NAT1 (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)	NAT1 (select a term)
intoGen	NAT1
NCG5 (London)	NAT1
Cancer3D	NAT1(select the gene name)
Impact of mutations	[PolyPhen2] [SIFT Human Coding SNP] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
	Diseases
OMIM	108345
Orphanet
Medgen	NAT1
Genetic Testing Registry	NAT1
NextProt	P18440 [Medical]
TSGene	9
GENETests	NAT1
Target Validation	NAT1
Huge Navigator	NAT1 [HugePedia]
snp3D : Map Gene to Disease	9
BioCentury BCIQ	NAT1
ClinGen	NAT1
	Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD	9
Chemical/Pharm GKB Gene	PA17
Clinical trial	NAT1
	Miscellaneous
canSAR (ICR)	NAT1 (select the gene name)
	Probes
	Litterature
PubMed	228 Pubmed reference(s) in Entrez
GeneRIFs	Gene References Into Functions (Entrez)
CoreMine	NAT1
EVEX	NAT1
GoPubMed	NAT1
iHOP	NAT1

REVIEW articles	automatic search in PubMed
Last year publications	automatic search in PubMed

Search in all EBI NCBI

indexed on : Fri Jun 30 11:13:00 CEST 2017

Home Genes Leukemias Solid Tumors Cancer-Prone Deep Insight Case Reports Journals Portal Teaching

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.